For example, ML385, a small molecule inhibitor of Nrf2, selectively alters therapeutic resistance in Keap1-deficient Non-small-cell lung carcinoma (NSCLC) tumors [99]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.